Indegene Limited — Investor Meet, 03-11-2025: Analysts/Institutional Investor Meet/Con. Call Updates

Indegene reported Q2 FY26 revenue of INR 804.2 Cr (+17.1% YoY, +5.7% QoQ). Adjusted EBITDA margin was 18.2%, impacted by wage hikes and strategic investments, leading to PAT of INR 102.1 Cr (+11.4% YoY).

Management noted reduced pharma industry uncertainty and strong demand for digital/AI solutions. Two >$3M ACV deals were signed, contributing to a healthy pipeline. Strategic investments in GenAI (Cortex, Tectonic) and acquisitions (BioPharm, WARN) are set to accelerate future growth, though this implies ~1.5% near-term margin compression, expected to recover within 6-8 quarters. Sentiment is positive on market opportunities.